- Home
- ILAG vs LGVN Comparison
ILAG vs LGVN Comparison
Compare ILAG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- LGVN
- Stock Information
- Founded
- ILAG 1981
- LGVN 2014
- Country
- ILAG Hong Kong
- LGVN United States
- Employees
- ILAG N/A
- LGVN N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- ILAG Consumer Discretionary
- LGVN Health Care
- Exchange
- ILAG Nasdaq
- LGVN Nasdaq
- Market Cap
- ILAG 18.4M
- LGVN 30.0M
- IPO Year
- ILAG 2022
- LGVN 2021
- Fundamental
- Price
- ILAG $0.98
- LGVN $2.05
- Analyst Decision
- ILAG
- LGVN Strong Buy
- Analyst Count
- ILAG 0
- LGVN 2
- Target Price
- ILAG N/A
- LGVN $8.00
- AVG Volume (30 Days)
- ILAG 47.1K
- LGVN 393.9K
- Earning Date
- ILAG 11-29-2024
- LGVN 11-08-2024
- Dividend Yield
- ILAG N/A
- LGVN N/A
- EPS Growth
- ILAG N/A
- LGVN N/A
- EPS
- ILAG N/A
- LGVN N/A
- Revenue
- ILAG $6,443,357.00
- LGVN $1,229,000.00
- Revenue This Year
- ILAG N/A
- LGVN $161.78
- Revenue Next Year
- ILAG N/A
- LGVN $8.62
- P/E Ratio
- ILAG N/A
- LGVN N/A
- Revenue Growth
- ILAG N/A
- LGVN 39.34
- 52 Week Low
- ILAG $0.33
- LGVN $0.77
- 52 Week High
- ILAG $1.35
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- ILAG 44.56
- LGVN 52.20
- Support Level
- ILAG $0.97
- LGVN $1.76
- Resistance Level
- ILAG $1.06
- LGVN $2.26
- Average True Range (ATR)
- ILAG 0.06
- LGVN 0.12
- MACD
- ILAG -0.01
- LGVN 0.05
- Stochastic Oscillator
- ILAG 16.32
- LGVN 58.00
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.